Marché mondial de l'insuffisance rénale aiguë (IRA) - Tendances et prévisions du secteur jusqu'en 2028

Analyse et perspectives du marché : marché mondial de l'insuffisance rénale aiguë (IRA)

Le marché de l'insuffisance rénale aiguë (IRA) devrait connaître une croissance exponentielle au cours de la période de prévision de 2021 à 2028. Data Bridge Market Research analyse que le marché croît à un TCAC de 5,10 % au cours de la période de prévision de recherche mentionnée ci-dessus. La population gériatrique augmente et la charge de morbidité de l'insuffisance rénale aiguë augmente, entre autres.  

L'augmentation de la population obèse et diabétique et l'incidence croissante de la dengue, du paludisme et de la leptospirose stimulent également la croissance du marché. De plus, l'augmentation de la recherche et du développement, la présence de nouveaux médicaments en cours de développement et l'augmentation des dépenses de santé constituent des opportunités pour la croissance du marché. Cependant, les effets indésirables causés par les médicaments, le manque de coordination des soignants et le cadre réglementaire strict pour l'approbation des médicaments peuvent parfois entraver le marché mondial de l'insuffisance rénale aiguë (IRA).

Acute renal failure (ARF) is characterized by the sudden loss of kidney ability to eliminate the excess of fluid, metabolic waste and salts from the body. This inability leads to accumulation of electrolytes and metabolic wastes in the body that leads to life-threatening issues. Acute kidney failure develops in less interval of time and has been reported mostly to affect the people who are already hospitalized especially in people who rely on intensive care. The most common symptom associated with ARF includes decrease urine output, fluid retention, fatigue, confusion, nausea, weakness, irregular heartbeat, chest pain, seizures among others. Primarily acute renal failure is prerenal, postrenal and intrarenal failure. Prerenal failure commonly arises due to depletion of intravascular volume, intrarenal arises due to tubules damage while postrenal is most commonly associated with obstruction of tracks. Moreover severe dehydration, autoimmune diseases, medication toxicity can also lead to ARF. Acute renal failure can be treated by balancing of body fluids, calcium supplements, potassium supplements and dialysis.

According to the publication of National Kidney Foundation Inc. over 2 million people worldwide receiving kidney associated disease treatment with either dialysis and kidney transplant. As the kidney affected people rising worldwide, they demands effective treatment and therapies hence expected to provide market with the lucrative growth.

This acute renal failure (ARF) market provides details of market share, new developments and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Global Acute Renal Failure (ARF) Market Scope and Market Size

Acute renal failure (ARF) market is segmented on the basis of type, diagnosis, treatment, end-users and distribution channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

• On the basis of type, the acute renal failure (ARF) market is segmented into prerenal, intrarenal, postrenal.
• On the basis of diagnosis, the acute renal failure (ARF) market is segmented into CT scan, kidney biopsy, ultrasound.
• On the basis of treatment, the acute renal failure (ARF) market is segmented into medications and dialysis. Medication segment is further sub-segmented into sodium bicarbonates, N-acetyl cysteine, statins, others.
• On the basis of end-users, the acute renal failure (ARF) market is segmented into clinics, hospitals, home healthcare, others.
• On the basis of distribution channel, the acute renal failure (ARF) market has also been segmented into direct tender, hospital pharmacy, retail pharmacy, online pharmacy and others. 

Acute renal failure (ARF) Market Country Level Analysis

Acute renal failure (ARF) market is analysed and market size information is provided by country, type, diagnosis, treatment, end-users and distribution channel as referenced above.

The countries covered in the Acute renal failure (ARF) market report are U.S., Canada, Mexico in North America, Brazil, Argentina, Peru, Rest of South America, as part of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa, as a part of Middle East and Africa.

On geographical estimation, North America accounts the largest market share due to the high awareness among the patients regarding disease symptoms and its treatment options and presence of major market players. Europe accounts the second largest market share due to due to high penetration of market players by taking strategic initiatives for enhancing their distribution channel. Asia-Pacific is expected to account for the largest market share over coming years for the acute renal failure (ARF) market due to increasing demand of effective treatment solutions and rising patient population.

The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Patient Epidemiology Analysis

Le marché de l'insuffisance rénale aiguë (IRA) vous fournit également une analyse de marché détaillée pour l'analyse des patients, le pronostic et les remèdes. La prévalence, l'incidence, la mortalité et les taux d'adhésion sont quelques-unes des variables de données disponibles dans le rapport. L'analyse d'impact directe ou indirecte de l'épidémiologie sur la croissance du marché est analysée pour créer un modèle statistique multivarié de cohorte plus robuste pour prévoir le marché au cours de la période de croissance.

Analyse du paysage concurrentiel et des parts de marché de l'insuffisance rénale aiguë (IRA)

Le paysage concurrentiel du marché de l'insuffisance rénale aiguë (IRA) fournit des détails par concurrent. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements dans la recherche et le développement, les nouvelles initiatives du marché, la présence mondiale, les sites et installations de production, les forces et les faiblesses de l'entreprise, le lancement de produits, les pipelines d'essais cliniques, les approbations de produits, les brevets, la largeur et l'étendue du produit, la domination des applications, la courbe de survie technologique. Les points de données ci-dessus fournis ne concernent que l'orientation des entreprises liée au marché de l'insuffisance rénale aiguë (IRA).

Français Les principaux acteurs couverts sur le marché de l'insuffisance rénale aiguë (IRA) sont Alloksys, Angion, Quark, AM-Pharma BV, Atox Bio, Astellas Pharma Inc., Pharming, MediBeacon, Exponential Biotherapies, Sequens, Pfizer Inc., Solvay, Leisha Pharma Solutions Pvt. Ltd., Merck KGaA, Wacker Chemie AG, Hetero Healthcare Limited., Zydus Cadila, Dr. Reddy's Laboratories, Novartis AG, Teva Pharmaceutical Industries Ltd., Glenmark Pharmaceutical Inc parmi d'autres acteurs nationaux et mondiaux. Les analystes de DBMR comprennent les atouts concurrentiels et fournissent une analyse concurrentielle pour chaque concurrent séparément.

SKU-60279